Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

A new topical treatment called RT1640 claims to reverse AGA using cyclosporine A, Minoxidil, and a new chemical entity, RT175. Users are skeptical due to lack of clinical trial data and inconsistent before-and-after photos.

Aminexil/Kopexil may help reduce hair loss by addressing perifollicular fibrosis in androgenetic alopecia, but it lacks the extensive clinical backing of finasteride and minoxidil. Some users find it effective, but availability and cost are issues, especially in the US where it's not FDA-approved.

Androgenic alopecia (AGA) might have evolved to reduce prostate cancer risk by increasing UV exposure to the scalp, but this theory is debated. Treatments like minoxidil and finasteride are used for AGA, though the exact causes and evolutionary reasons for hair loss are unclear.

The conversation discusses using GHK Cu + AHK Cu peptides combined with topical dutasteride and minoxidil for hair regrowth. It mentions negative side effects of finasteride and promotes a specific copper peptide serum.

The conversation is about finding a solution for scalp inflammation related to AGA, with the user expressing frustration that Minoxidil and Finasteride do not address inflammation. The user has researched glucocorticoids and topical NSAIDs for reducing inflammation and seeks advice from specialists.

GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

OP is considering Bicalutamide for female AGA and TE but is concerned about its side effects and effectiveness compared to Finasteride. OP is also using Minoxidil and Spironolactone but is experiencing significant shedding and is unsure if it's androgen-driven or due to Minoxidil changes.

A 19-year-old diagnosed with AGA was refused finasteride by a dermatologist who cited fertility concerns and prescribed minoxidil, vitamins, and shampoos instead. The user is unsure about using minoxidil and considers finding another dermatologist.

A user with Androgenetic Alopecia is seeking advice on hair growth treatments while planning for pregnancy. Current routine includes LaserCap, Nizoral Shampoo, scalp massage, The Ordinary Multi Peptide Serum, vitamin D, prenatal vitamins, and SEEN shampoo.

Clascoterone (Breezula) is anticipated for release in the coming years but is considered too weak for aggressive androgenetic alopecia (AGA). Current treatments like minoxidil, finasteride, and dutasteride are preferred, with some users obtaining clascoterone from the gray market.

The solution contains minoxidil, finasteride, azelaic acid, caffeine, retinoic acid, and procapil. Users suggest minoxidil with tretinoin and a 5-alpha reductase inhibitor, while dismissing retinoic and azelaic acids as unnecessary.

A peptide from Japanese water chestnut fruit may help with hair loss by suppressing DHT's effect on hair follicle cell death, potentially serving as a finasteride alternative. The treatment's effectiveness and safety in humans remain uncertain.

A 22-year-old female with AGA due to PCOS is using 5% minoxidil foam and 2mg finasteride daily, and is seeking advice on microneedling frequency and safety. Concerns about finasteride dosage and its effects on PCOS were discussed, with emphasis on trusting the prescribed treatment plan.

Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.

Spironolactone and finasteride are not recommended for women planning pregnancy due to birth defect risks. Both need to be stopped months before conception, and finasteride is generally not advised for women.

The conversation discusses interest in peptides for hair loss, specifically mentioning ahkCU and ghkCU. A user is considering adding ghkCU to their treatment regimen.

The conversation is about using a DIY topical Cetirizine 1% solution with microneedling for hair loss treatment. Concerns were raised about potential side effects and the effectiveness of Cetirizine for this purpose.

Clascoterone results are anticipated to be released in fall 2026, possibly at the EADV conference. Users express skepticism and humor about the release date.

GT20026 is discussed as a potential treatment for hair loss that targets androgen receptors without affecting hormone levels, but it may not promote significant regrowth. It is expected to be available by 2028, with other treatments like Breezula and Clascoterone also mentioned.

The conversation is about finding a clearnet vendor for clascoterone, also known as Winlevi, for hair loss treatment. The user is seeking recommendations via direct message.

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

A user with AGA uses topical spironolactone 2% due to side effects from the oral form and is concerned about its use during conception and breastfeeding. They seek alternatives to prevent AGA relapse while planning pregnancy and after childbirth.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

AHK-Cu peptide is considered better than GHK-Cu for hair growth. The user is seeking recommendations for trusted AHK-Cu peptide brands with third-party testing.

Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.

PP405 shows initial promise for treating androgenetic alopecia, with safety confirmed in early trials, but skepticism remains due to limited data. Further trials are needed to determine its true efficacy and potential market impact.

SCUBE3 is available online but poses risks like tumor promotion and high costs. Users advise against using it due to health concerns and inefficacy as a standalone treatment.

Clascoterone is a topical treatment for androgenetic alopecia, showing modest to moderate hair regrowth, and may be available by 2027-2028. It is considered safer than finasteride, with discussions on its effectiveness compared to RU58841 and pyrilutamide.

Dutasteride is more effective than finasteride for hair loss, with some users experiencing fewer side effects. Users share experiences with dutasteride, finasteride, minoxidil, and biotin, discussing dosage and fertility concerns.